---
title: "BeOne Medicines AG (ONC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ONC.US.md"
symbol: "ONC.US"
name: "BeOne Medicines AG"
industry: "Biotechnology"
datetime: "2026-05-20T18:41:17.961Z"
locales:
  - [en](https://longbridge.com/en/quote/ONC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ONC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ONC.US.md)
---

# BeOne Medicines AG (ONC.US)

## Company Overview

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [beonemedicines.com](https://beonemedicines.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: B (0.24)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 11 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 37.44% |  |
| Net Profit YoY | 230.75% |  |
| P/B Ratio | 6.93 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 33009891584.74 |  |
| Revenue | 5739192000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 12.42% | B |
| Profit Margin | 8.94% | B |
| Gross Margin | 88.95% | A |
| Revenue YoY | 37.44% | A |
| Net Profit YoY | 230.75% | A |
| Total Assets YoY | 46.43% | A |
| Net Assets YoY | 36.03% | A |
| Cash Flow Margin | 250.45% | A |
| OCF YoY | 37.44% | A |
| Turnover | 0.80 | B |
| Gearing Ratio | 44.35% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - BeOne Medicines AG",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "37.44%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "230.75%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "6.93",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "33009891584.74",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "5739192000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "12.42%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "8.94%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "88.95%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "37.44%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "230.75%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "46.43%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "36.03%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "250.45%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "37.44%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.80",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "44.35%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 64.34 | 54/386 | 558.48 | 503.06 | 114.73 |
| PB | 6.93 | 370/386 | 9.55 | 8.97 | 7.94 |
| PS (TTM) | 5.75 | 119/386 | 7.93 | 7.44 | 6.48 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-20T04:00:00.000Z

Total Analysts: **28**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 19 | 68% |
| Overweight | 8 | 29% |
| Hold | 1 | 4% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 305.36 |
| Highest Target | 498.00 |
| Lowest Target | 333.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ONC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ONC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ONC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ONC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**